Paysign, Inc. provides prepaid card programs, patient affordability offerings, digital banking, life science software technology solutions, and integrated payment processing services for businesses, consumers, and government institutions in the United States. The company offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card and software solutions. It also operates a customer service center; and offers a communication suite, including mobile app, two-way SMS, text alerts, and cardholder web portal. It markets its prepaid card solutions under the Paysign brand name. The company serves companies and municipalities that require payment solutions for rewards, rebates, payment assistance, and other payments to their customers, employees, agents, and others. Paysign, Inc. was founded in 2001 and is headquartered in Henderson, Nevada.…
Paysign: 3 Key Takeaways for Long-Term Investors
Paysign (NASDAQ: PAYS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Software - Infrastructure industry, part of the Technology sector, and reports about 226 employees.
The shares were at 9.790 USD on 20 November 2026, up 91.6% over 52 weeks. Its 52-week range is 3.080 USD to 16.15 USD: the price is 39.4% below the high and 217.9% above the low.
At a market capitalisation of 556.60M USD, it trades at 29.7 times trailing earnings and 15.9 times forward earnings. The median trailing P/E of its 14 largest Software - Infrastructure peers is 36.9, a discount of 20% for PAYS.
Paysign reports return on equity of 15.6%, an operating margin of 19.6% and revenue up 42.6% year over year.
It holds more cash than debt, a net cash position of 29.04M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 14.81 USD is 51.3% above the current price. The next earnings report is expected on 23 March 2027.